← Patent-cliff monitor small molecule TABRECTA CAPMATINIB HYDROCHLORIDE
Loss of exclusivity July 2035 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name TABRECTA Active ingredient CAPMATINIB HYDROCHLORIDE Strength EQ 200MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2020 Marketing status RX
Listed patents Patent Expires Type 10596178 July 2035 product 12208101 July 2035 product 7767675 November 2032 substance, product 8420645 June 2031 substance, product 8901123 May 2029 use U-2813 12084449 November 2027 use U-2813 8461330 November 2027 substance, product
Regulatory exclusivity Code Expires ODE-291 May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.